Regulatory agencies and pharmacopeia organizations revised policies and guidelines in 2019.
FDA issued guidance documents that address patient-centric drug development, biosimilars, and a variety of biologics application guidelines. The US Pharmacopeial Convention (USP) also proposed some changes to monographs. A few notable actions taken this year are reviewed.
Read this article in BioPharm International’s September 2019 Regulatory Sourcebook.
BioPharm International
eBook: Regulatory Sourcebook, September 2019
September 2019
Pages: 7–9
When referring to this article, please cite it as BioPharm International Editors, “What’s New in Regulations and Compliance," BioPharm International Regulatory Sourcebook eBook (September 2019).
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.